Physician profile
Luis A Guzman
NPI 1114297330
$5,300.95
in general payments reported to CMS, 2019-2025
26 companies · $570 in 2025
The $570 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $840 · 2021: $1,071 · 2022: $660 · 2023: $617 · 2024: $536 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,245.70 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $1,012.26 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $866.39 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $793.29 | 2019-2025 | Airsupra, Farxiga, Evusheld |
| Ironwood Pharmaceuticals, INC | $215.52 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $178.74 | 2021-2024 | Eliquis, Camzyos |
| Dynavax Technologies Corporation | $111.66 | 2021-2023 | Heplisav-B |
| Exact Sciences Corporation | $109.92 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $93.94 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $78.37 | 2019-2020 | |
| Abbvie INC. | $66.65 | 2021-2022 | |
| Dexcom, INC. | $65.25 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $63.56 | 2022 | |
| Organon LLC | $61.98 | 2022-2023 | Nexplanon |
| Biohaven Pharmaceuticals, INC. | $54.97 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.60 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $40.80 | 2022 | |
| Phadia US INC. | $29.93 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $28.46 | 2025 | Enflonsia, Capvaxive, Gardasil 9 |
| Sanofi Pasteur INC. | $26.79 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.86 | 2023 | Rexulti |
| Shield Therapeutics INC | $22.30 | 2023 | Accrufer |
| Amarin Pharma, INC. | $19.92 | 2021 | |
| Amgen INC. | $19.61 | 2023 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $16.66 | 2023 | Rexulti |
| Biosense Webster, INC. | $13.82 | 2025 | Nuvision Ice Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.